AACR Cancer Progress Report 2012
Cantley, L. C., W. S. Dalton, R. N. DuBois, O. J. Finn, P. A. Futreal, T. R. Golub, W. N. Hait, et al. 2012. “AACR Cancer Progress Report 2012”. Clin Cancer Res 18: S1-100.
Search
Search results
289 results found
The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways
Carroll, M., M. H. Tomasson, G. F. Barker, T. R. Golub, and D. G. Gilliland. 1996. “The TEL/Platelet-Derived Growth Factor Beta Receptor (PDGF Beta R) Fusion in Chronic Myelomonocytic Leukemia Is a Transforming Protein That Self-Associates and Activates PDGF Beta R Kinase-Dependent Signaling Pathways”. Proc Natl Acad Sci U S A 93: 14845-50.
Initial genome sequencing and analysis of multiple myeloma
Chapman, M. A., M. S. Lawrence, J. J. Keats, K. Cibulskis, C. Sougnez, A. C. Schinzel, C. L. Harview, et al. 2011. “Initial Genome Sequencing and Analysis of Multiple Myeloma”. Nature 471: 467-72.
Targetable genetic features of primary testicular and primary central nervous system lymphomas
Chapuy, B., M. G. Roemer, C. Stewart, Y. Tan, R. P. Abo, L. Zhang, A. J. Dunford, et al. 2016. “Targetable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas”. Blood 127: 869-81.
Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors
Chattopadhyay, S., A. L. Stewart, S. Mukherjee, C. Huang, K. A. Hartwell, P. G. Miller, R. Subramanian, et al. 2015. “Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor With Improved Selectivity over Hematopoietic Progenitors”. Cell Rep 10: 755-70.
The Drug Repurposing Hub: a next-generation drug library and information resource
Corsello, S. M., J. A. Bittker, Z. Liu, J. Gould, P. McCarren, J. E. Hirschman, S. E. Johnston, et al. 2017. “The Drug Repurposing Hub: A Next-Generation Drug Library and Information Resource”. Nat Med 23: 405-8.
Identification of AML1-ETO modulators by chemical genomics
Corsello, S. M., G. Roti, K. N. Ross, K. T. Chow, I. Galinsky, D. J. DeAngelo, R. M. Stone, A. L. Kung, T. R. Golub, and K. Stegmaier. 2009. “Identification of AML1-ETO Modulators by Chemical Genomics”. Blood 113: 6193-205.
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression
Ding, Z., C. J. Wu, G. C. Chu, Y. Xiao, D. Ho, J. Zhang, S. R. Perry, et al. 2011. “SMAD4-Dependent Barrier Constrains Prostate Cancer Growth and Metastatic Progression”. Nature 470: 269-73.
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity
Dulak, A. M., P. Stojanov, S. Peng, M. S. Lawrence, C. Fox, C. Stewart, S. Bandla, et al. 2013. “Exome and Whole-Genome Sequencing of Esophageal Adenocarcinoma Identifies Recurrent Driver Events and Mutational Complexity”. Nat Genet 45: 478-86.
Gene expression-based screening for inhibitors of PDGFR signaling
Antipova, A. A., B. R. Stockwell, and T. R. Golub. 2008. “Gene Expression-Based Screening for Inhibitors of PDGFR Signaling”. Genome Biol 9: R47.